{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:10:43Z","timestamp":1779250243313,"version":"3.51.4"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are known for their durable efficacy and favorable tolerance profiles. However, elderly patients are often underrepresented in clinical trials. The manifestation of immune-related adverse events (irAEs) in elderly patients with different tumor types remains unclear. This study aimed to compare irAEs in elderly patients with gastrointestinal and lung cancers receiving ICIs and to provide real-world safety data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study included elderly patients (\u226570 years) with gastrointestinal (GI) tumors or lung cancer who received \u22652 cycles of ICIs across multiple departments within a single academic medical center between January 2016 and February 2022. A 2:1 propensity score matching was used to balance baseline characteristics between the cohorts. The primary endpoint was the incidence of any-grade irAEs between GI tumors and lung cancer, whereas secondary analyses focused on organ-specific toxicities. Statistical comparisons were performed using the chi-squared test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The overall incidence of any-grade irAEs was higher in elderly patients with lung cancer than in those with GI tumors (61.0%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 47.9%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013). After matching for baseline characteristics, the lung cancer group still showed a trend toward a higher incidence of irAEs (61.7%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 50.8%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.056). Notably, patients with GI tumors had a higher incidence of skin toxicity (28.7%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 15.1%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), whereas patients with lung cancer had a higher incidence of thyroid dysfunction (28.1%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 11.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Elderly patients with lung cancer were more likely to experience irAEs during immunotherapy than those with GI tumors. However, dermatological toxicities were more common in elderly patients with GI tumors, whereas thyroid dysfunction was more frequently observed in those with lung cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004069","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T03:00:48Z","timestamp":1775530848000},"page":"1512-1520","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Immune-related adverse events between elderly patients with gastrointestinal and lung cancers: A real-world study"],"prefix":"10.1097","volume":"139","author":[{"given":"Infong","family":"Chan","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingdong","family":"Kong","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Jia","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxiao","family":"Dong","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"He","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xumeng","family":"Ji","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guomei","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Illness, Taiyuan Central Hospital, Taiyuan, Shanxi 030009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yantai Harbour Hospital, Yantai, Shandong 264099, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihao","family":"Lu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"R1-20260520","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","article-title":"Comparative analysis of cancer statistics in China and the United States in 2024","volume":"137","author":"Wu","year":"2024","journal-title":"Chin Med J"},{"key":"R2-20260520","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf"},{"key":"R3-20260520","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: Geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"Lancet Oncol"},{"key":"R4-20260520","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2021.03.199","article-title":"Immunotherapy use outside clinical trial populations: Never say never?","volume":"32","author":"Rzeniewicz","year":"2021","journal-title":"Ann Oncol"},{"key":"R5-20260520","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","article-title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: A systematic review and meta-analysis of randomized clinical trials","volume":"31","author":"Magee","year":"2020","journal-title":"Ann Oncol"},{"key":"R6-20260520","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-018-0336-8","article-title":"Efficacy of PD-1 & PD-L1 inhibitors in older adults: A meta-analysis","volume":"6","author":"Elias","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R7-20260520","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.seminoncol.2018.08.007","article-title":"FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies","volume":"45","author":"Marur","year":"2018","journal-title":"Semin Oncol"},{"key":"R8-20260520","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R9-20260520","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","article-title":"CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations","volume":"127","author":"Felip","year":"2020","journal-title":"Eur J Cancer"},{"key":"R10-20260520","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R11-20260520","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2022.6901","article-title":"Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy","volume":"9","author":"Voruganti","year":"2023","journal-title":"JAMA Oncol"},{"key":"R12-20260520","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jgo.2018.07.015","article-title":"The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population","volume":"10","author":"Sattar","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"R13-20260520","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jgo.2022.05.013","article-title":"Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: an observational study","volume":"13","author":"Storm","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"R14-20260520","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2019.08.030","article-title":"Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer","volume":"137","author":"Galli","year":"2019","journal-title":"Lung Cancer"},{"key":"R15-20260520","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00262-023-03417-3","article-title":"Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: A retrospective, multicenter, real-world cohort study","volume":"72","author":"Xiao","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"R16-20260520","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/liv.15405","article-title":"Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma","volume":"42","author":"Vithayathil","year":"2022","journal-title":"Liver Int"},{"key":"R17-20260520","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.08.030","article-title":"Efficacy and safety of immune checkpoint inhibitors in elderly patients (\u226570 years) with squamous cell carcinoma of the head and neck","volume":"157","author":"Saleh","year":"2021","journal-title":"Eur J Cancer"},{"key":"R18-20260520","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"R19-20260520","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"R20-20260520","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41585-020-0286-z","article-title":"The microbiome and gynaecological cancer development, prevention and therapy","volume":"17","author":"Laniewski","year":"2020","journal-title":"Nat Rev Urol"},{"key":"R21-20260520","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"R22-20260520","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R23-20260520","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s11427-022-2218-x","article-title":"Cancer statistics in Chinese older people, 2022: Current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea","volume":"66","author":"Ju","year":"2023","journal-title":"Sci China Life Sci"},{"key":"R24-20260520","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"R25-20260520","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R26-20260520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","article-title":"Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials","volume":"107","author":"Kanjanapan","year":"2019","journal-title":"Eur J Cancer"},{"key":"R27-20260520","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol Int"},{"key":"R28-20260520","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.arr.2013.04.003","article-title":"The impact of ageing on natural killer cell function and potential consequences for health in older adults","volume":"12","author":"Hazeldine","year":"2013","journal-title":"Ageing Res Rev"},{"key":"R29-20260520","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0167-5699(00)01714-X","article-title":"Ageing of lymphocytes and lymphocytes in the aged","volume":"21","author":"Globerson","year":"2000","journal-title":"Immunol Today"},{"key":"R30-20260520","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1189\/jlb.1103592","article-title":"Aging and innate immune cells","volume":"76","author":"Plackett","year":"2004","journal-title":"J Leukoc Biol"},{"key":"R31-20260520","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.smim.2012.04.003","article-title":"Signaling pathways in aged T cells - a reflection of T cell differentiation, cell senescence and host environment","volume":"24","author":"Goronzy","year":"2012","journal-title":"Semin Immunol"},{"key":"R32-20260520","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1478-811X-12-2","article-title":"Downregulation of inhibitory SRC homology 2 domain-containing phosphatase-1 (SHP-1) leads to recovery of T cell responses in elderly","volume":"12","author":"Le Page","year":"2014","journal-title":"Cell Commun Signal"},{"key":"R33-20260520","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"185","author":"Morad","year":"2022","journal-title":"Cell"},{"key":"R34-20260520","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R35-20260520","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"R36-20260520","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41577-023-00884-8","article-title":"Localization, tissue biology and T cell state - implications for cancer immunotherapy","volume":"23","author":"Schenkel","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"R37-20260520","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40487-019-0096-8","article-title":"A review of immune-mediated adverse events in melanoma","volume":"7","author":"Kennedy","year":"2019","journal-title":"Oncol Ther"},{"key":"R38-20260520","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","article-title":"Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy","volume":"14","author":"Suresh","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R39-20260520","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pccm.2023.08.003","article-title":"Exploring the microbiome: Uncovering the link with lung cancer and implications for diagnosis and treatment","volume":"1","author":"Yi","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"R40-20260520","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5905357","article-title":"Tobacco smoking and liver cancer risk: Potential avenues for carcinogenesis","volume":"2021","author":"Jain","year":"2021","journal-title":"J Oncol"},{"key":"R41-20260520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2023-007305","article-title":"Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R42-20260520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105427","article-title":"Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors","volume":"109","author":"Liu","year":"2024","journal-title":"EBioMedicine"},{"key":"R43-20260520","article-title":"Roles of the gut microbiota in immune-related adverse events: Mechanisms and therapeutic intervention","volume":"1\u201314","author":"Gao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R44-20260520","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R45-20260520","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"R46-20260520","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R47-20260520","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"R48-20260520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159539","article-title":"Intestinal microbiota promotes psoriasis-like skin inflammation by enhancing Th17 response","volume":"11","author":"Zakostelska","year":"2016","journal-title":"PLoS One"},{"key":"R49-20260520","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: Mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"R50-20260520","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R51-20260520","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"R52-20260520","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"R53-20260520","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"R54-20260520","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"R55-20260520","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"R56-20260520","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R57-20260520","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1242\/dev.113.4.1093","article-title":"The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain","volume":"113","author":"Lazzaro","year":"1991","journal-title":"Development"},{"key":"R58-20260520","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.21037\/jtd.2019.04.102","article-title":"Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer","volume":"11","author":"Koyama","year":"2019","journal-title":"J Thorac Dis"},{"key":"R59-20260520","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"R60-20260520","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Cardona","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R61-20260520","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1079074","article-title":"Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer","volume":"14","author":"Iwamoto","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R62-20260520","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"R63-20260520","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:01:36Z","timestamp":1779249696000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004069","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2025-08-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}